REPROCELL News

Hyderabad India – 15 September 2021: Bioserve Biotechnologies India Pvt. Ltd. (a 100% owned subsidiary of REPROCELL Inc) will sponsor a webinar series hosted by the Society of Fetal Medicine in September. The title of the webinar is “Genetic Testing in Fetal Medicine-Navigating the Maze”.

Continue reading

Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company SOPARBIOTECH INTERNATIONAL.

Continue reading

Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company Soparbiotech International.

Continue reading

Glasgow, UK: REPROCELL Europe Ltd, a subsidiary of REPROCELL Inc., has signed a non-exclusive distributorship agreement with Helicon Company, one of the leading suppliers of research equipment and consumables in Russia. 

Continue reading

Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).

Continue reading

Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs).

Continue reading

Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian variants. These have all been identified as Variants of Concern (VOC) by the World Health Organization.

Continue reading

We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial for the treatment of spinocerebellar ataxia in Japan. The safety and efficacy of Stemchymal will continue to be investigated during a certain observation period.

Continue reading

Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.

Continue reading

REPROCELL USA and REPROCELL Europe will be attending all 5 days of the Biotechgate Digital Partnering 2021 Event, 3-7 May 2021. 

Partnering scheduling is now open, and registration is free. 
Have a one-on-one Zoom meeting with our experts and get to know our capabilities of life sciences.

We may be a good partner for you in your research projects! We have included an overview of our available services below:

Continue reading